+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 130Years
All Genders
ID07029737

Evaluating Acalabrutinib Combined with R-CHOP Chemotherapy for Untreated Mantle Cell Lymphoma in Spain Phase II Trial

Led by AstraZeneca · Updated on 2026-10-27

55

Participants Needed

22

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of acalabrutinib combined with the standard chemotherapy regimen R-CHOP for patients with mantle cell lymphoma MCL who have not received prior treatment. This phase II, single-arm, open-label study in Spain aims to understand how well this combination works as a first-line treatment and to monitor patient safety during the process. The study involves approximately 55 participants across multiple centers. Participants will receive acalabrutinib orally twice daily along with up to six 21-day cycles of R-CHOP chemotherapy during the induction phase. After completing six cycles, those who tolerate the treatment and whose disease is not progressing will continue acalabrutinib alone. Participants who respond to treatment will also receive maintenance doses of rituximab every other 28-day cycle for up to 12 doses. Following this maintenance, acalabrutinib monotherapy continues until disease progression or treatment discontinuation. Throughout the study, participants will be regularly assessed with clinical evaluations, including monitoring for response to treatment and safety. The main outcome measured is the best overall response rate approximately one year after starting acalabrutinib. Secondary outcomes include time to response, duration of response, progression-free survival, overall survival, and safety profiles. Participants will be followed from screening until withdrawal, loss to follow-up, death, or study end, with a maximum follow-up of about 30 months after the last participant enrolls.

CONDITIONS

Brief Title

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here